Abstract
We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ER alpha)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT-PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ER alpha-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Cohort Studies
-
Disease-Free Survival
-
Estrogen Antagonists / therapeutic use*
-
Estrogen Receptor alpha
-
Female
-
Genes
-
Glycoprotein Hormones, alpha Subunit / genetics
-
Glycoprotein Hormones, alpha Subunit / metabolism*
-
Humans
-
Middle Aged
-
Postmenopause
-
RNA, Neoplasm / biosynthesis
-
Receptor, ErbB-2
-
Receptors, Estrogen / analysis*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tamoxifen / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Biomarkers, Tumor
-
Estrogen Antagonists
-
Estrogen Receptor alpha
-
Glycoprotein Hormones, alpha Subunit
-
RNA, Neoplasm
-
Receptors, Estrogen
-
Tamoxifen
-
Receptor, ErbB-2